Regenxbio (RGNX) Total Liabilities (2014 - 2025)

Regenxbio's Total Liabilities history runs 12 years deep, the most recent figure standing at $350.3 million for Q4 2025.

• On a quarterly basis, Total Liabilities rose 69.77% year-over-year to $350.3 million in Q4 2025; TTM through Dec 2025 was $350.3 million, a 69.77% increase from a year earlier, with the FY2025 full-year figure at $350.3 million, up 69.77% from the prior year.
• Total Liabilities eased to $350.3 million in Q4 2025 per RGNX's latest filing, from $363.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $367.3 million in Q2 2025 and bottomed at $206.3 million in Q4 2024.
• The 5-year median for Total Liabilities is $318.5 million (2022), against an average of $295.6 million.
• Across the five-year window, Total Liabilities surged 642.14% in 2021 and dropped 21.31% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $349.6 million in 2021, then fell by 9.31% to $317.1 million in 2022, then dropped by 17.3% to $262.2 million in 2023, then fell by 21.31% to $206.3 million in 2024, then soared by 69.77% to $350.3 million in 2025.
• Per Business Quant, the three latest RGNX Total Liabilities figures stand at $350.3 million (Q4 2025), $363.8 million (Q3 2025), and $367.3 million (Q2 2025).